Hebbar L, Dorman B H, Clair M J, Roy R C, Spinale F G
Department of Anesthesia and Perioperative Medicine, Medical University of South Carolina, Charleston 29425-2207, USA.
Anesthesiology. 1997 Mar;86(3):649-59. doi: 10.1097/00000542-199703000-00018.
Although propofol (2-6 di-isopropylphenol) is commonly used to induce and maintain anesthesia and sedation for surgery, systematic hypotension and reduced cardiac output can occur in patients with or without intrinsic cardiac disease. The effect of propofol on myocyte contractility after the development of congestive heart failure (CHF) remains unknown. This study tested the hypothesis that propofol would have direct effects on myocyte contractile function in both healthy and CHF cardiac myocyte preparations.
Isolated left ventricular (LV) myocyte contractile function (shortening velocity, micron/s) was examined in myocytes from five control pigs and in five pigs with pacing-induced CHF (240 beats/min, for 3 weeks) in the presence of propofol concentrations ranging from 1-6 micrograms/ml. In addition, myocyte contractility in response to beta-adrenergic receptor stimulation (isoproterenol, 10-50 nM) in the presence of propofol (3 micrograms/ml) was examined.
Three weeks of pacing caused LV dysfunction consistent with CHF as evidenced by increased LV end-diastolic diameter (control 3.3 +/- 0.1 cm vs. CHF 5.6 +/- 0.2 cm; P < 0.05) and reduced LV fractional shortening (control 34 +/- 3% vs. CHF 12 +/- 2%, P < 0.05). Propofol (6 micrograms/ml) caused a concentration-dependent negative effect on velocity of shortening from baseline in both control (67 +/- 2 microns/s vs. 27 +/- 3 microns/s; P < 0.05) and CHF myocytes (29 +/- 1 microns/s vs. 15 +/- 1 microns/s; P < 0.05). Importantly, CHF myocytes were more sensitive than control myocytes to the negative effects of propofol on velocity of shortening at the lower concentration (1 microgram/ml). beta-adrenergic responsiveness was reduced by propofol (3 micrograms/ml) in control myocytes only.
Propofol has a direct and negative effect on basal myocyte contractile processes in the setting of CHF, which is more pronounced than that on healthy myocytes at reduced propofol concentrations.
尽管丙泊酚(2,6 - 二异丙基苯酚)常用于诱导和维持手术麻醉及镇静,但无论有无心脏基础疾病的患者都可能出现系统性低血压和心输出量降低。丙泊酚对充血性心力衰竭(CHF)发生后心肌细胞收缩性的影响尚不清楚。本研究检验了以下假设:丙泊酚对健康和CHF心肌细胞制剂中的心肌细胞收缩功能均有直接影响。
在丙泊酚浓度范围为1 - 6微克/毫升的情况下,检测了五只对照猪和五只起搏诱导的CHF猪(240次/分钟,持续3周)的左心室(LV)分离心肌细胞的收缩功能(缩短速度,微米/秒)。此外,还检测了在丙泊酚(3微克/毫升)存在的情况下,β - 肾上腺素能受体刺激(异丙肾上腺素,10 - 50纳摩尔)时的心肌细胞收缩性。
起搏三周导致LV功能障碍,符合CHF表现,表现为LV舒张末期直径增加(对照组3.3±0.1厘米,CHF组5.6±0.2厘米;P < 0.05)和LV缩短分数降低(对照组34±3%,CHF组12±2%,P < 0.05)。丙泊酚(6微克/毫升)对对照组(67±2微米/秒对27±3微米/秒;P < 0.05)和CHF心肌细胞(29±1微米/秒对15±1微米/秒;P < 0.05)的缩短速度均产生浓度依赖性的负性影响。重要的是,在较低浓度(1微克/毫升)时,CHF心肌细胞比对照心肌细胞对丙泊酚对缩短速度的负性影响更敏感。丙泊酚(3微克/毫升)仅降低了对照心肌细胞的β - 肾上腺素能反应性。
在CHF情况下,丙泊酚对基础心肌细胞收缩过程有直接的负性影响,在丙泊酚浓度降低时,这种影响在CHF心肌细胞中比在健康心肌细胞中更明显。